Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 2/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 2/20 | 0.35 |
| ▸ | RXRB | P28702 | 2/20 | 0.35 |
| ▸ | RXRG | P48443 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29410000 | 0.91 | LPL (0.41) | LPLLIPGROCK1BACE1CA1 | |
| SCHEMBL2011756 | 0.91 | LPL (0.41) | LPLLIPGROCK1BACE1CA1 | |
| SCHEMBL29409998 | 0.91 | LPL (0.41) | LPLLIPGROCK1BACE1CA1 | |
| SCHEMBL2016481 | 0.89 | LPL (0.40) | LPLLIPGROCK1BACE1P2RX7 | |
| SCHEMBL10158676 | 0.85 | LPL (0.40) | LPLLIPGROCK1BACE1P2RX7 | |
| SCHEMBL30935010 | 0.85 | LPL (0.40) | LPLLIPGROCK1BACE1P2RX7 | |
| SCHEMBL16998416 | 0.83 | LPL (0.42) | LPLLIPGROCK1BACE1P2RX7 | |
| SCHEMBL15241249 | 0.82 | RXRA (0.34) | RXRARXRBRXRG | |
| SCHEMBL4158988 | 0.82 | LPL (0.44) | LPLLIPGROCK1BACE1P2RX7 | |
| SCHEMBL5781980 | 0.82 | LPL (0.46) | LPLLIPGBACE1P2RX7CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062015-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| US-9062015-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| US-9062015-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| EP-2513057-B1 | SPHINGOSINE KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2013-09-04 | — | — | EP | disclosed |
| EP-2513057-B1 | SPHINGOSINE KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2013-09-04 | — | — | EP | disclosed |
| EP-2513057-A1 | SPHINGOSINE KINASE INHIBITORS | Merck Patent GmbH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252789-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252789-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252789-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
| WO-2011072791-A1 | SPHINGOSINE KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011072791-A1 | SPHINGOSINE KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252789-A1 | INHIBITORS OF SPHINGOSINE KINASE | SPHK1, SPHK2, S1PR3 | LPL 2372/4885LIPG 1527/4885ROCK1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.